Preoperative CA 125 levels were measured in 36 patients with advanced epithelial ovarian carcinoma in clinical response undergoing a second-look operation. All the patients had positive levels (> 35 U/ml) of this tumor marker at diagnosis. The correlation between antigen levels and disease status at surgery revealed a sensitivity of this assay of 0.55 (only 11/20 patients still with tumor had positive levels) and a specificity of 0.94 (15/16 patients with no tumor had < 35 U/ml). The predictive value of a positive test was 0.92. This method unfortunately proved unable to recognize microscopic residual tumor burden, less than 0.5 cm.
BerekJ.S., HackerN.F.Staging and second-look operations in ovarian cancer. In: DeppeG., ed. Ovarian Cancer.New York: AR Liss, 1984; 363–74.
2.
GoldhirschA., TrillerJ.K., GreinerR., DreherE., DavisB.W.Computed tomography prior to second-look operation in advanced ovarian cancer. Obstet Gynecol, 1983; 62: 630–4.
3.
KabawatS.E., BastR.C.Jr., WelchW.R., KnappR.C., ColvinR.B.Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens on human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Path1983; 79: 98–104.
4.
BastR.C.Jr., KlugT.L., St. JohnE.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med., 1983; 309: 883–7.
5.
KlugT.L., BastR.C.Jr., NiloffJ.M., KnappR.C., ZurawskiVR.Jr.A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res., 1984; 44: 1048–53.
6.
BastR.C.Jr., KlugT.L., SchaetzlE.Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9 and CEA. Am J Obstet Gynecol, 1984; 149: 553–9.
7.
CanneyP.A., MooreM., WilkinsonPM, JamesR.D.Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer1984; 50: 765–9.
8.
DoddJ., TylerJ.P.P., RandonA.J.The value of monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes. Br J Obstet Gynecol, 1985; 92: 1054–60.
9.
ZanaboniF., VergadoroF., PrestiM., GallottiP., LombardiF., BolisG.Tumor antigen CA 125 as a marker of ovarian epithelial carcinomaGynecol. Oncol. (in press).
10.
NiloffJ.M., BastR.C.Jr., SchaetzlE.M., KnappR.C.Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol.1985; 151: 981–6.
11.
AtackD.B., NiskerJ.A., AllenH.H., TustanoffER, LevinL.CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstel Gynecol.1986; 154: 287–9.
12.
BerekJ.S., KnappR.C., MalkasianG.D.CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol.1986; 67: 685–9.
13.
MartoniA., BelluccoA., MarabiniA.CA 125 monitoring during chemotherapy for ovarian cancer. Int J Biol Markers.1986; 3: 121–8.
14.
MangioniC., BolisG., MolteniP., BelloniC.Indications, advantages and limitations of laparoscopy in ovarian cancer. Gynecol Oncol., 1979; 7: 47.
